BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform

+1.26% Pre

Alphabet Inc. Class A

GOOGL

337.12

337.65

+1.26%

+0.16% Pre

April 6 (Reuters) - Alphabet Inc GOOGL.O:

STIPPLE BIO EMERGES FROM STEALTH WITH OVERSUBSCRIBED $100 MILLION SERIES A FINANCING TO ADVANCE STP-100 INTO EARLY CLINICAL STUDIES AND ADVANCE A PRECISION ONCOLOGY PIPELINE THAT LEVERAGES ITS POINTILLIST PLATFORM
STIPPLE BIO: FINANCING CO-LED BY RA CAPITAL, A16Z BIO+HEALTH AND NEXTECH INVEST, AND EXISTING INVESTORS INCLUDING GOOGLE VENTURES
STIPPLE BIO: PROCEEDS FROM FINANCING, WHICH SHOULD FUND CO INTO 2029, TO ADVANCE LEAD CANDIDATE STP-100

Source text: ID:nGNX8yLbG7

Further company coverage: GOOGL.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.